Showing 2111-2120 of 7282 results for "".
Fillers for the Décolletage Area
https://practicaldermatology.com/topics/practice-management/fillers-for-the-dcolletage-area/21113/Fillers offer patients an alternative to device-based interventions for chest rejuvenation.o, MDWhat Will Be Our Legacy?
https://practicaldermatology.com/topics/practice-management/what-will-be-our-legacy/21434/Practical Dermatology® Magazine Welcomes Neal Bhatia, MD, FAAD as Co-Chief Medical EditorOn Dosage and Diet: Isotretinoin 101
https://practicaldermatology.com/topics/general-topics/on-dosage-and-diet-isotretinoin-101/21445/Isotretinoin is one of the most essential agents in the treatment of acne, but dietary and dosage considerations must be made to maximize efficacy. Author:Joshua Zeichner, MD“Natural” Remedies for Eczema: Evidence for the Alternative?
https://practicaldermatology.com/topics/general-topics/natural-remedies-for-eczema-evidence-for-the-alternative/22936/Limited data suggest the possibility that some natural agents may be particularly useful in the treatment of atopic dermatitis.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuJournal Club: What's New in Pathogenesis and Treatment of Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-whats-new-in-pathogenesis-and-treatment-of-atopic-dermatitis/26247/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Jason E. Hawkes, MD, a dermatologist practicing in the Sacramento area, and a member of the Practical Dermatology Editorial Board, about the latest research on the pathogenesis of and treatment targets for atopic dermatitis (AD).Noah Worcester 2024: Dr. Hinshaw on Onychomycosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-hinshaw-onychomycosis/24587/Molly Hinshaw, MD, FAAD, summarizes her lecture on diagnosis and management of onychomycosis at the 2024 Noah Worcester Dermatological Society meeting.Therapeutics Update: Exploring Current Treatments for Diverse Conditions
https://practicaldermatology.com/topics/therapeutics-update/therapeutics-update-exploring-current-treatments-diverse-conditions/24562/Chief Medical Editor Neal Bhatia, MD, FAAD, and the Practical Dermatology® team convened an expert roundtable to discuss therapeutic treatment strategies for vitiligo, alopecia areata, hidradenitis suppurativa, and chronic spontaneous urticaria—the latest options, what has fallen out of favor, challAtopic Dermatitis and Psoriasis: Treatments, Considerations, and What’s Coming
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-and-psoriasis-treatments-considerations-and-whats-coming/24038/Atopic dermatitis (AD) and plaque psoriasis (PsO) are two of the most common cutaneous conditions we treat in dermatology. While these chronic inflammatory disorders have similarities, regarding chronic skin disease burden and impact on quality of life, they may diverge when considering clinical preAI-based DermGPT Focuses on Improved Clinic Productivity
https://practicaldermatology.com/topics/practice-management/ai-based-dermgpt-focuses-on-improved-clinic-productivity/23990/With Faranak Kamangar, MD; an interview by Heidi W. Moore